Welcome to our dedicated page for Capital Bancorp SEC filings (Ticker: CBNK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Capital Bancorp, Inc. (NASDAQ: CBNK) SEC filings page on Stock Titan provides access to the company’s official U.S. Securities and Exchange Commission disclosures, along with AI-powered summaries to help interpret complex documents. As a publicly traded bank holding company for Capital Bank, N.A., Capital Bancorp files periodic reports, current reports, and other regulatory documents that describe its financial condition, risk profile, capital structure, and governance.
Investors can review Form 10-K annual reports for a comprehensive discussion of business segments such as commercial banking, mortgage banking, credit cards, government loan servicing, and corporate activities, as well as risk factors and management’s analysis. Form 10-Q quarterly reports provide interim updates on net interest income, fee revenue, loan and deposit growth, allowance for credit losses, and the impact of transactions like the Integrated Financial Holdings, Inc. acquisition.
Form 8-K current reports are particularly relevant for CBNK, documenting material events such as quarterly earnings releases, cash dividend declarations, changes in executive officers, board appointments, and planned redemptions of subordinated notes. These filings give timely insight into management decisions, capital actions, and leadership changes.
Users can also access proxy statements for information on board structure, director independence, and compensation of non-employee directors, as referenced in the company’s description of its governance practices. Where applicable, Form 4 insider trading reports reveal transactions by directors and executive officers in CBNK shares.
Stock Titan’s interface surfaces new filings in near real time from EDGAR and applies AI-generated highlights so readers can quickly identify key points—such as changes in dividend policy, credit quality metrics, or capital instruments—without reading every page. This makes it easier to analyze Capital Bancorp’s regulatory history and ongoing disclosure record.
Randall James Levitt reported insider transactions in Capital Bancorp, Inc. (CBNK). On 08/26/2025 he sold 2,662 shares at $34.41 and on 08/27/2025 he sold 37,338 shares at $34.37. The Form 4 lists multiple indirect holdings: 97,338 shares held by Montrose Lending Group, LLC; 266,665 by the Randall James Levitt Revocable Trust; 30,700 by RJL Investment Company, LLC; 154,056 by Maud Associates, LLC; and 452,000 by BTC Trust Company of South Dakota. Reported derivative holdings include stock options totaling 11,681 underlying shares and 811 restricted stock units vesting 03/03/2026. The form is signed by an attorney-in-fact on 08/28/2025.
Capital Bancorp reported stronger core results for the quarter ended June 30, 2025, with growth across loans, deposits and earnings following its IFH acquisition. Total assets reached $3.389 billion, up from $3.207 billion, driven by portfolio loans of $2.748 billion gross and cash and cash equivalents of $274.6 million. Deposits rose to $2.941 billion from $2.762 billion. Net interest income increased to $47.6 million from $37.1 million, and the company recorded quarterly net income of $13.136 million ($0.79 basic EPS) versus $8.205 million a year earlier. Total noninterest income doubled to $13.1 million, partly from government lending and servicing, while noninterest expenses increased to $39.6 million, including merger-related costs. Credit metrics show rising delinquencies and nonaccruals ($36.2 million) and an ACL of $47.4 million. The IFH acquisition added scale with $83.5 million consideration and goodwill of $22.5 million after a $1.4 million measurement adjustment.
Capital Bancorp (CBNK) Form 4: EVP & CFO Dominic C. Canuso bought 600 common shares on 07/31/2025 at $31.11, a cash outlay of roughly $18.7 k. His direct holding rises to 4,834 shares.
The filing lists unexercised equity incentives: 2,000 options at $21.57 (expire 07/15/2029), 1,754 options at $30.51 (expire 03/03/2030), plus 2,773 RSUs that begin vesting between 07/15/2025 and 03/03/2026. Each RSU converts 1-for-1 into common stock; no derivative disposals occurred.
The buy increases Canuso’s stake by about 14% and represents the first reported open-market purchase since his last option grant, potentially signaling executive confidence. However, the dollar value is modest relative to CBNK’s market capitalization and daily volume.